CAPTRUST Financial Advisors
SNDX icon

CAPTRUST Financial Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,563
Closed -$223K – 3387
2026
Q1 		$223K Buy
+9,563
New +$208K ﹤0.01% 2604
2022
Q3 		– Sell
-288
Closed -$6K – 3760
2022
Q2 		$6K Hold
288
– – ﹤0.01% 4014
2022
Q1 		$5K Sell
288
-23
-7% -$387 ﹤0.01% 4169
2021
Q4 		$7K Hold
311
– – ﹤0.01% 3925
2021
Q3 		$6K Hold
311
– – ﹤0.01% 3885
2021
Q2 		$5K Hold
311
– – ﹤0.01% 3878
2021
Q1 		$7K Buy
+311
New +$7.03K ﹤0.01% 3609

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

CAPTRUST Financial Advisors's SNDX Position: Q2 2026 in Review

CAPTRUST Financial Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 9,563 shares — an estimated $223K sold.

CAPTRUST Financial Advisors first reported a position in SNDX in Q1 2021 and held it in 7 quarters. The position peaked at $223K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • CAPTRUST Financial Advisors reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 9,563 Syndax Pharmaceuticals shares in Q2 2026, an estimated $223K.
  • CAPTRUST Financial Advisors first reported a position in Syndax Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Syndax Pharmaceuticals position peaked at $223K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.